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Probiotics and carriage of 
Streptococcus pneumoniae 
serotypes in Danish children, 
a double-blind randomized 
controlled trial
Sine Fjeldhøj1, Rikke Pilmann Laursen2, Anni Larnkjær2, Christian Mølgaard2, Kurt Fuursted1, 
Karen Angeliki Krogfelt  1 & Hans-Christian Slotved  1
This study examined the carriage of Streptococcus pneumoniae in healthy Danish children aged 8–19 
months and assessed the effect of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium 
animalis subsp lactis on the pneumococcal carriage during daycare enrolment. Potential risk factors of 
pneumococcal carriage were analysed and the carriage study was compared with registered invasive 
pneumococcal disease (IPD) data. This study is a part of the ProbiComp study, which was a double-blind, 
randomized controlled trial, including 290 children allocated to probiotics or placebo for 6 months and 
recruited during two autumn seasons (2014/2015). Pneumococci were identified by optochin sensitivity, 
bile solubility, α-hemolysis and/or capsular reaction. Serotyping was performed by latex agglutination 
kit and Quellung reaction. The carriage rate of S. pneumoniae was 26.0% at baseline and 67.4% at 
the end of intervention. No significant difference was observed between the placebo group and the 
probiotics group (p = 0.508). Children aged 8–19 months were carriers of non-pneumococcal vaccine 
serotypes causing IPD in children aged 0–4 years. However, serotypes causing most IPD cases in Danish 
elderly were either not found or found with low prevalence suggesting that children are not the main 
reservoir of those serotypes and other age groups need to be considered as carriers.
Streptococcus pneumoniae can cause invasive pneumococcal disease (IPD) which worldwide is associated with 
high mortality and morbidity at all ages despite the use of effective vaccines1. S. pneumoniae colonizes the epi-
thelium of the nasopharynx and at least 92 different serotypes are known2,3. S. pneumoniae can cause meningitis, 
otitis media, pneumonia, sinusitis and bacteremia primarily in young children and elderly4.
Carriage of S. pneumoniae is a prerequisite for developing IPD, and is most frequent in young children, 
who act as reservoirs4. High carriage rate is associated with a high prevalence of respiratory infections5 and it 
is believed that children transmit IPD serotypes to other age groups6–8. However, transmission from adults to 
children is also observed8. Potential risk factors of pneumococcal carriage include attending daycare, young 
age, having siblings in daycare, having siblings <5 years and genetic and environmental factors such as soci-
oeconomic conditions and passive smoking4,9,10. Daycare attendance is considered a major risk factor9,11,12. The 
currently available vaccines protect against a limited number of the known serotypes3. The 7-valent pneumococ-
cal conjugate vaccine (PCV7) was included in the Danish Childhood Immunization Program in 2007 and was 
replaced by PCV13 in 20101. PCV7 includes serotype 4, 6B, 9V, 14, 18C, 19F, and 23F while PCV13 includes the 
PCV7-serotypes and additional serotypes 1, 3, 5, 6A, 7F, and 19A1,7. PCV7 led to a significant reduction in IPD 
caused by PCV7-serotypes markedly among children aged <2 years1,3,6,13, but also a significant reduction in IPD 
cases and carriage of vaccine serotypes among older children and adults was seen, especially in the age group 
65+ years3,8. This phenomenon is known as herd protection8. With the reduction of PCV-serotypes, an increase 
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in the incidences of IPD caused by non-vaccine serotypes has been observed1,6,7. Thus, it is important to continue 
surveillance of serotype distribution.
Only a few pneumococcal carriage studies in children have been conducted in Denmark, the most recent was 
prior to the introduction of PCV79.
The purpose of this study was to assess the effect of probiotics on S. pneumoniae carriage in healthy Danish 
children aged 8–19 months, determine serotype distribution and analyse risk factors for pneumococcal carriage. 
Furthermore, to assess whether the carried serotypes are also isolated in IPD cases of all age groups as described 
by Slotved et al. (2016)14,15 and Harboe et al.16.
Methods
Study population. This study is part of the ProbiComp study, which was a randomised, double-blind, place-
bo-controlled parallel study investigating the effect of probiotics on infections in young children starting daycare 
described in details in Laursen et al.17.
The ProbiComp study included 290 healthy children aged 8–13 months starting daycare within 12 weeks 
after start of intervention. They were randomly assigned to a combination of the probiotics Lactobacillus 
rhamnosus GG (LGG) and Bifidobacterium animalis subsp lactis (BB-12), administered orally, in a dose of 109 
colony-forming units/day (CFU/day) of each or placebo (maltodextrin) for 6 months. Children were examined 
at baseline before start of intervention and 6 months later at the end of intervention. The children were recruited 
during two autumn seasons from mid-August to mid-December in 2014 and 2015. LGG and BB-12 are reg-
istered trademarks of Chr. Hansen A/S. For exclusion criteria see Laursen et al.17. Study design, compliance, 
randomisation, data collection, outcome measurements and sample size calculation are described in Laursen 
et al.17. Briefly, both parents and study personnel were blinded to group allocation, and the placebo powder 
and the probiotics powder did not differ in smell, taste or colour. Parents registered daily whether the child had 
ingested the product and by the end of intervention the parents returned the registration sheets and unused 
sachets with powder to evaluate compliance. PCV13 is administered in a 2 + 1 dose schedule at the age of 3, 5 
and 12 months1. At baseline 98.2% of the children examined were covered by at least one dose of PCV13, while 
92.6% were covered by two doses. At the end of intervention 88.0% of the children were covered by all three doses 
of PCV13. Vaccination data were obtained at the Danish Vaccination Register (DDV) (record number 2015-57-
0102). Information regarding the children’s background and health were obtained by interviewing parents and 
during the intervention period occurrence of children’s symptoms of illness, absence from daycare, doctor’s visits, 
and doctor-diagnosed illnesses were registered by the parents in weekly and daily web-based questionnaires17.
Nasal swab sampling. Two autumn seasons were included in the study. At baseline, samples were analysed 
from 141 children from the first season (2014) and 144 children from the second season (2015). At the end of 
intervention, samples from 124 children from the first season and 134 children from the second season were 
analysed.
Nasal swab samples were collected by a modified version of Satzke et al.18. Minitip flocked swabs 
(FLOQSwabs™, Copan, Italy) were used to take the samples. The swabs were inserted as far as possible into the 
nasal cavity and rotated, although within the limitations of the children’s comfort. They were then placed in 1 mL 
Luria-Bertani (LB) broth with 10% glycerol in cryotubes, and stored at −80 °C until analysis.
Identification of pneumococcal serotypes. Identification of pneumococcal serotypes was performed as 
previously described4. Briefly, 10 µL of each sample was added to 3 mL serum-ox broth and incubated overnight 
at 37 °C in 5% CO2, before plating. The following day 1 µL of each serum-ox broth was cultured on 10% horse 
blood agar plates, which were incubated overnight at 37 °C, 5% CO2. S. pneumoniae were identified based on 
optochin sensitivity, bile solubility, α-hemolysis and/or capsular reaction (Quellung reaction). Pneumotest latex 
agglutination kit (SSI Diagnostica, Hillerød, Denmark) was performed on the serum-broth to determine pneu-
mococcal group. Serotypes were identified by the Quellung reaction (Neufeld test) using serotype specific antisera 
(SSI Diagnostica, Hillerød, Denmark). The specimens were screened by pneumotest latex agglutination kit for 
multiple serotypes. If multiple serotypes were found, they were isolated and serotyped.
Invasive pneumococcal disease data. Data on invasive pneumococcal isolates in the period 2014–2016 
were obtained from the Danish laboratory surveillance system at the National Neisseria and Streptococcus 
Reference Laboratory (NSR), Statens Serum Institut (SSI) as described by Slotved et al. (2016)14,15. Briefly, infor-
mation on age and serotype was used. An IPD case was defined as S. pneumoniae occurring in normally sterile 
sites such as cerebrospinal fluid or blood. The coverage and evaluation of the database in Denmark was described 
by Harboe et al.16.
Data analysis. RStudio version 1.0.136 and R version 3.4.1 for Windows was used for calculation of 
odds ratios (OR), confidence intervals (95% CI), and p-values using two tailed Fisher’s Exact Test (http://
www.r-project.org/ last accessed: 02.20.2018). A p-value < 0.05 was considered significant. RStudio was also used 
to make graphical illustrations.
We examined several risk factors for pneumococcal carriage including sex, having siblings <5 years, breast-
feeding at baseline examination, living with a dog or cat, passive smoking exposure in the household, having 
respiratory infections such as bronchitis, pneumonia or otitis media during the intervening period and the effect 
of receiving antibiotics during the intervening period of 6 months. We did not have access to dates on when anti-
biotics were received. Univariate logistic regression was not undertaken as confounders were evenly distributed 
during the randomization process, therefore multivariate logistic regression was not required. Crude odds ratio 
of pneumococcal carriage was estimated in each characteristic (sex, having siblings <5, breastfeeding, respiratory 
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infections including bronchitis, pneumonia and otitis media, antibiotic use, passive smoking exposure and expo-
sure to cats or dogs) using two-tailed Fisher’s exact test.
Ethical considerations. The ProbiComp study protocol was approved by the Committees on Biomedical 
Research Ethics for the Capital Region of Denmark (H-4-2014-032), and we hereby confirm that all methods 
were performed according to the guidelines and regulations approved by the Committees on Biomedical Research 
Ethics. The study was registered at clinicaltrials.gov (identifier NCT02180581 (Supplementary file), posted 
02/07/2014)17. Informed consent from parents and legal guardians of the children was required. Participation in 
the study was voluntary and parents could withdraw their consent at any time17.
Regarding IPD data, no ethical approval or informed consent was required since data were collected routinely 
for national surveillance purposes. Using the data is approved by the Danish Data Protection Agency (record 
number 2007-41-0229).
Results
Carriage study. The carriage rate of S. pneumoniae at baseline of the two seasons were comparable with 
no statistical significant difference between the two seasons as seen in Table 1. Hence, the two seasons were 
combined as one baseline group for further analysis. The mean carriage rate at baseline therefore was 26.0% (CI 
20.8–31.1%) (Table 1).
At the end of intervention half of the children had received the probiotics LGG and BB-12 for 6 months, hence 
each season included both a placebo group and a probiotics given group (Table 1). The two seasons were alike 
with no statistical significant difference between the two placebo groups and the two probiotics groups, hence 
data were combined into one placebo group and one probiotics group (Table 1).
The carriage rate of S. pneumoniae in children receiving the probiotics LGG and BB-12 was 69.5% (CI 61.6–
77.5%) while the carriage rate in the placebo group was 65.4% (CI 57.2–73.6%). Thus, probiotics do not have a 
significant effect on the pneumococcal carriage rate (p = 0.508) (Table 1). Furthermore, the serotype diversity/
distribution in the probiotics group and placebo group were not significantly different (data not shown). The 
placebo group and the probiotics group were therefore combined into one group representing the end of inter-
vention for further analysis. The carriage rate at the end of intervention was 67.4% (CI 61.7–73.2%), which is 
significantly higher than the carriage rate at baseline (p < 0.001) (Table 1).
All the cases of multiple serotype carriage involved two serotypes except one child at the end of intervention, 
who carried three serotypes (Table 2).
The 81 isolates found at baseline belonged to 21 different serotypes and 1 serogroup (where serotyping was not 
possible) (Fig. 1). The most common serotype isolated at baseline was serotype 21 constituting 13.6% of all iso-
lates. Serotype 23B, 35F and 11A were also commonly isolated, constituting 12.3%, 11.1% and 11.1% of all isolates 
respectively (Fig. 1). The only PCV13-serotypes isolated at baseline were 19A and 19F, which both constituted 
2.5% of all isolates.
At the end of intervention we found 185 isolates belonging to 24 different serotypes. Serotype 11A was the 
most common serotype constituting 16.2% of all isolates. Serotype 23B, 15B, 21, 23A and 35F were also common, 
constituting 10.8%, 8.1%, 8.1%, 8.1% and 7.6% of all isolates respectively (Fig. 1). Serotype 4, 19F and 6A were 
the only PCV13-serotypes found at the end of intervention, only constituting 1.1%, 0.5% and 0.5% of all isolates 
respectively (Fig. 1).
Serotype 8 was only found in two children at baseline (Fig. 1).
Carriage rate, % 
(95% CI) OR (95% CI)* p-value*
Baseline
  Season 1 (2014) 27.7 (20.3–35.0%) 1.00 1.00
  Season 2 (2015) 24.3 (17.3–31.3%) 0.840 (0.477–1.477) 0.589
End of intervention
Season 1 placebo group 60.7 (48.4–72.9%) 1.00 1.00
Season 2 placebo group 69.6 (58.7–80.4%) 1.478 (0.674–3.268) 0.356
Season 1 probiotics group 76.2 (65.7–86.7%) 1.00 1.00
Season 2 probiotics group 63.1 (51.3–74.8%) 0.536 (0.229–1.228) 0.127
  Placebo group 65.4 (57.2–73.6%) 1.00 1.00
Probiotics group 69.5 (61.6–77.5%) 1.207 (0.694–2.107) 0.508
Overall carriage rate
  Baselinea 26.0 (20.8–31.1%) 1.00 1.00
End of interventionb 67.4 (61.7–73.2%) 5.884 (4.007–8.715) <0.001c
Table 1. Comparison of carriage rate of the two seasons and a comparison of the placebo groups and the 
probiotics groups. Odds ratios (OR) and p-values were calculated by two-tailed Fisher’s exact test. aMean of 
season 1 (2014) and season 2 (2015). bMean of the placebo group and the probiotics group. cComparison of the 
baseline and the end of intervention. *Calculated by Fisher’s Exact Test in RStudio. CI: confidence intervals, OR: 
odds ratio.
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Risk factors. Sex did not influence the carriage rate of S. pneumoniae significantly (p = 0.280 at baseline and 
p = 0.187 at end of intervention) (Tables 3 and 4).
Having siblings <5 years significantly increased the carriage rate of S. pneumoniae in children at baseline 
(p < 0.001), but did not influence the carriage rate of children at the end of intervention (p = 0.883) (Tables 3 and 
4).
Breastfeeding at the time of baseline examination, receiving systemic antibiotics during the intervention 
period, exposure to passive smoking or living with a dog or cat did not influence the carriage rate of S. pneumo-
niae (Tables 3 and 4).
We examined if children with respiratory infections during the intervening period had an increased risk of 
pneumococcal carriage, but no significant difference in carriage rate was observed between children having had 
respiratory infections or children not affected by respiratory infections (p = 0.425) (Table 4). However, children 
who had experienced bronchitis during intervention seemed to have a lower carriage rate compared to children 
who had not experienced bronchitis (p = 0.031), but this result may not be reliable due to the low number of 
children in the cohort (Table 4). Serotype distribution in children who have experienced bronchitis, pneumonia 
or otitis media is shown in Fig. 2.
Registered invasive pneumococcal diseases in Denmark. Data regarding IPD-causing serotypes in 
Denmark were obtained from the Danish laboratory surveillance system as mentioned in the methods section 
and Fig. 3 shows the data. Serotype 24F caused most of the IPDs in Denmark among 0–4 years old children in 
2014 and 2015. Other commonly isolated serotypes from this patient group was 10A, 15C and 21 in 2014 and 
8, 12F, 33F, 11A and 38 in 2015. In 2016 serotype 8 was causing most of the IPDs among 0–4 years old and the 
second most common serotype isolated was 24F.
Among 5–64 years old serotype 8 was causing most of the registered IPDs in both 2014–2016. Among 65+ 
years old serotype 8 was also causing most of the IPD cases in Denmark in 2014–2016. Serotype 3, 7F, 9N, 22F and 
12F were also common serotypes isolated in patients aged 65+ years in 2014–2016.
Baseline End of intervention
Number of children 
analyzed 285 258
Age 8–13 months 14–19 months
Year of swab sample 
collection 2014 and 2015 (autumn) 2015 and 2016 (spring)
Carriage rate, % (N) 26.0 (74) 67.4 (174)
Proportion carriers with >1 
serotype, % (N) 2.5 (7) 4.3 (11)
Proportion carriers with >2 
serotype, % (N) 0 (0) 0.4 (1)
Table 2. Carriage rate and proportion of carriers with multiple serotypes. N: number of carriers.
Figure 1. Carriage study and serotype distribution in Danish children at baseline and at the end of 
intervention. Grey color indicates PPV23-serotypes, black is non-PPV23 serotypes. Serotypes are listed with 
PCV7-serotypes first, then PCV13-serotypes followed by non-PCV13-serotypes.
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Discussion
To our knowledge this is the first carriage study of S. pneumoniae in children after the introduction of PCV in 
Denmark in 2007.
Oral administration of probiotics to children aged 8–13 months for 6 months had no effect on the carriage 
of pneumococcal serotypes as tested in two different years (2014 and 2015). Furthermore, we found an overall 
carriage rate in children attending daycare (end of intervention) of 67.4% as compared to a carriage rate of 69% 
before the introduction of PCV7 into the Danish Childhood Immunization Program9,19. Thus, PCV-use seems 
not to have influenced the overall carriage rate in children.
Pneumococcal vaccine-serotypes such as 6A, 23F, 14 and 19F, were frequently observed as carried serotypes in 
Denmark prior to the introduction of PCVs9. Our study revealed that vaccine-serotypes have almost disappeared 
in Danish children aged <2 years after the introduction of PCV13 and have been replaced by non-vaccine sero-
types such as 11A, 23B, 23A, 21, 15B, 15C, 35F and 35B (Fig. 1) as observed in other countries7,10,20–22.
Living with siblings <5 years of age significantly increased the risk of pneumococcal carriage before starting 
in daycare (baseline) (p < 0.001) (Table 3). This has also been observed by others10–12. We found no significant 
difference in carriage rate of S. pneumoniae among children receiving probiotics and children receiving placebo 
(Table 1). Nasopharyngeal carriage of S. pneumoniae is considered a prerequisite for developing pneumococcal 
associated diseases such as otitis media, pneumonia, bronchitis and other respiratory infections5,23,24. Wong et 
al. reported that the probiotic LGG inhibits the adherence of S. pneumoniae to human epithelial cells in vitro25. 
Clinical studies investigating the effect of administrating probiotics on the incidence of respiratory tract infec-
tions have shown inconclusive results. Laursen et al.17 did not find LGG and BB-12 to reduce the number of 
days absent from daycare because of respiratory or gastrointestinal infections in the same children as included 
in our study, and the probiotics did not affect the endogenous gut microbiota composition in those children26. A 
Swedish study involving 248 healthy children aged 1–5 years and attending daycare showed a significantly lower 
incidence of otitis media in children who ingested milk with 107 CFU/mL Lactobacillus rhamnosus LB21 com-
pared to placebo27. However, a study including 309 otitis media-prone children aged 10 months to 6 years showed 
no significant difference in the incidence of otitis media or nasopharyngeal carriage of S. pneumoniae between 
the group receiving capsules containing probiotics (8–9 × 109 CFU/capsule) and the placebo group28. Others 
found that LGG and Bifidobacterium lactis ingested orally reduced the risk of otitis media and recurrent respira-
tory infections in children <2 years29, as did milk containing LGG in healthy children aged 1–6 years30, while 
Skovbjerg et al.31 report that nasal delivery of the probiotic Lactobacillus rhamnosus did not affect nasopharyngeal 
pneumococcal carriage in children aged 1–8 years with secretory otitis media31.
The carriage rate at the end of intervention was significantly higher than at baseline (p < 0.001) (Table 1). The 
age difference between these two groups was small (8–13 months at baseline and 14–19 months at the end of 
intervention), and the use of probiotics during intervention did not affect the carriage rate (Table 1), hence these 
Number of carriers (total 
number of children)
Carriage rate % 
(95% CI) OR (95% CI)* p-value*
Baseline
Sex
Females 32 (140) 22.9 (15.9–29.8%) 1.00 1.00
Males 42 (145) 29.0 (21.6–36.3%) 1.375 (0.781–2.436) 0.280
Siblings <5 years
No** 14 (148) 9.5 (4.7–14.2%) 1.00 1.00
Yes 49 (94) 52.1 (42.0–62.2%) 10.299 (5.043–22.217) <0.001
Breastfeeding at baseline 
examination
No 32 (150) 21.3 (14.8–27.9%) 1.00 1.00
Yes 42 (135) 31.1 (23.3–38.9%) 1.662 (0.944–2.950) 0.078
Respiratory infections during 
intervening period ***
No N/A N/A N/A N/A
Yes N/A N/A N/A N/A
Bronchitis
No N/A N/A N/A N/A
Yes N/A N/A N/A N/A
Pneumonia
No N/A N/A N/A N/A
Yes N/A N/A N/A N/A
Otitis media
No N/A N/A N/A N/A
Yes N/A N/A N/A N/A
Systemic antibiotic during 
intervening period
No N/A N/A N/A N/A
Yes N/A N/A N/A N/A
Passive smoking
No 67 (247) 27.1 (21.6–32.7%) 1.00 1.00
Yes 7 (38) 18.4 (6.1–30.7%) 0.608 (0.215–1.495) 0.322
Living with a dog or cat
No 56 (221) 25.3 (19.6–31.1%) 1.00 1.00
Yes 14 (47) 29.8 (16.7–42.9%) 1.249 (0.574–2.608) 0.584
Table 3. Potential risk factors for pneumococcal carriage in the baseline group and at the end of study. The table 
shows number of carriers, total number of children, carriage rates, p-values, odds ratios (OR) and confidence 
intervals (CI). *Odds ratios, confidence intervals and p-values were calculated by two-tailed Fisher’s Exact Test. 
**No siblings at all ***including bronchitis, pneumonia, sore throat, sinusitis, croup and otitis media N/A = not 
available. CI: confidence interval, OR: odds ratio.
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factors could not be the reason for this difference. Baseline samples were collected during autumn season, while 
samples at the end of intervention were collected 6 months later (spring season), however the effect of seasonality 
on the carriage of S. pneumoniae is not clear4. The children were not attending daycare at baseline, while all the 
children attended daycare at the end of intervention. Attending daycare is considered an important risk factor in 
relation to acquisition of pneumococcal carriage9,11,12, hence the higher carriage rate at the end of intervention 
might be explained by daycare attendance.
Since we consider our data non-parametric and the general choice of statistical test within this field is 
two-tailed Fishers exact test we have used the univariate analysis by two-tailed Fisher’s Exact Test to calculate the 
risk factors. This is not an age-matched group however the range of the age group is very small and we have not 
found studies showing such small age range to chance the carriage rate but external factors do chance the carriage 
rate such as daycare attendance9,11,12. Most studies include children aged 0–24 months as one group3,4,7,9,20,29 and 
since the children included in our study are aged 8–19 months we believe the age range is not significant. The 
main differences between the baseline group (aged 8–13 months) and end of intervention group (aged 14–19 
months) is daycare attendance and whether the children have received probiotics or not.
It is believed that children with high colonization rates of S. pneumoniae are the key transmitters of 
non-vaccine serotypes causing IPD to other age groups6,8,22,32. IPD caused by vaccine-serotypes has declined 
significantly after the implementation of PCV in children, while IPD caused by non-vaccine serotypes has 
increased8,14,33. This is consistent with the decline in carriage of vaccine-serotypes and an increase in carriage 
of non-vaccine serotypes in children which is supported here (Fig. 1) and by others7,20,22,34. Despite the use of 
effective vaccines, serotypes 3, 7F and 19A, which are included in PCV13, are still causing IPD among elderly in 
Denmark13,14 (Fig. 3). The low carriage rate of serotype 8 among 8–19 months old Danish children in our study 
contrasts the high prevalence of serotype 8 seen among elderly patients with IPD in Denmark. The other 5 most 
common serotypes (3, 22F, 9N, 12F and 7F) isolated from elderly with IPD in 2014–2016 were either not found 
or found with low prevalence (Figs 1 and 3). It has been assumed that immunization of infants alone would result 
in herd immunity and hence protect adults and elderly against disease caused by vaccine-serotypes21,35,36. Our 
findings suggest that children aged 8–19 months are not the main reservoir of serotypes causing IPD in elderly, 
but suggest that other age groups need to be considered as main carriers of some pneumococcal serotypes.
We detected that children aged 8–19 months were carriers of serotypes 24F, 10A, 11A, 15A, 15B, 21, which 
cause IPD in children aged 0–4 years (Figs 1 and 3).
The limitation of this study is that it included a narrow age group of children (8–19 months) and that the 
study only included children living in the capital region of Denmark. The strength of the study is, that we have 
Number of carriers (total 
number of children) Carriage rate % (95% CI) OR (95% CI)* p-value*
End of intervention
Sex
Females 90 (126) 71.4 (63.5–79.3%) 1.00 1.00
Males 84 (132) 63.6 (55.4–71.8%) 0.701 (0.400–1.222) 0.187
Siblings <5 years
No** 89 (130) 68.5 (60.5–76.4%) 1.00 1.00
Yes 59 (88) 67.0 (57.2–76.9%) 0.938 (0.506–1.748) 0.883
Breastfeeding 
at baseline 
examination
No 89 (134) 66.4 (58.4–74.4%) 1.00 1.00
Yes 85 (124) 68.5 (60.4–76.7%) 1.102 (0.633–1.922) 0.791
Respiratory 
infections during 
intervening 
period***
No 97 (139) 69.8 (62.2–77.4%) 1.00 1.00
Yes 77 (119) 64.7 (56.1–73.3%) 0.795 (0.456–1.384) 0.425
Bronchitis
No 164 (236) 69.5 (63.6–75.4%) 1.00 1.00
Yes 10 (22) 45.5 (24.6–66.3%) 0.367 (0.135–0.975) 0.031
Pneumonia
No 149 (222) 67.1 (60.9–73.3%) 1.00 1.00
Yes 25 (36) 69.4 (54.4–84.5%) 1.113 (0.495–2.650) 0.85
Otitis media
No 127 (182) 69.8 (63.1–76.5%) 1.00 1.00
Yes 47 (76) 61.8 (50.9–72.8%) 0.703 (0.387–1.285) 0.244
Systemic antibiotic 
during intervening 
period
No 113 (163) 69.3 (62.2–76.4%) 1.00 1.00
Yes 61 (95) 64.2 (54.8–73.9%) 0.795 (0.45–1.41) 0.411
Passive smoking
No 152 (226) 67.3 (61.1–73.4%) 1.00 1.00
Yes 22 (32) 68.8 (52.7–84.8%) 1.071 (0.458–2.669) 1
Living with a dog 
or cat
No 141 (200) 70.5 (64.2–76.8%) 1.00 1.00
Yes 24 (42) 57.1 (42.2–72.1%) 0.559 (0.268–1.181) 0.103
Table 4. Potential risk factors for pneumococcal carriage in the baseline group and at the end of intervention. 
The table shows number of carriers, total number of children, carriage rates, p-values, odds ratios (OR) and 
confidence intervals (CI). *Odds ratios, confidence intervals and p-values were calculated by two-tailed Fisher’s 
Exact Test. **No siblings at all ***including bronchitis, pneumonia, sore throat, sinusitis, croup and otitis media 
N/A = not available. CI: confidence interval, OR: odds ratio.
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examined very young children who usually are difficult to collect swab samples from and were able to obtain 
detailed background information regarding the participants.
In conclusion, this study revealed that PCV-serotypes have disappeared in children and been replaced by 
non-PCV serotypes after the introduction of PCVs in Denmark. The probiotics LGG and BB-12 did not prevent 
carriage of S. pneumoniae in children attending daycare. Having a sibling <5 years before daycare increased the 
risk of pneumococcal carriage significantly. Children aged 8–19 months are carriers of pneumococcal serotypes 
causing IPD in children aged 0–4 years. However, the children seem not to be carriers of serotypes causing the 
majority of IPD cases in elderly in Denmark.
Figure 2. Serotypes and number of isolates found in children who have experienced bronchitis, pneumonia 
and/or otitis media in the intervening period between baseline and the end of intervention. Infections were 
at any time during the intervening period. Serotypes are mentioned as PCV7-serotypes first, then PCV13-
serotypes followed by non-PCV13-serotypes.
Figure 3. Serotypes found in patients with IPD aged 0–4 years, 5–64 years and 65+ years. The figure shows 
IPD incidences per 100.000. Serotypes are mentioned as PCV7-serotypes first, then PCV13-serotypes followed 
by non-PCV13-serotypes. Data were obtained from the Danish laboratory surveillance system at the National 
Neisseria and Streptococcus Reference Laboratory (NSR), Statens Serum Institut (SSI) as described by Slotved et 
al. (2016)14,15.
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